tbuckley/cabot-search huggingface dataset:
Diseases of the Stomach.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Penicillin-Resistant Gonococcal Polyarthritis
Authors: Martin I. Leftik
Journal: JAMA (1978)

PENICILLIN has been the preferred treatment of gonococcal infections for years. However, in 1976, reports from Great Britain and the United States described patients with uncomplicated genitourinary infections due to penicillin-resistant<i>Neisseria gonorrhoeae</i>, which produced β-lactamase (penicillinase).<sup>1,2</sup>We describe a patient with infection of the pharynx and destructive polyarthritis due to a β-lactamase—producing strain of<i>N gonorrhoeae</i>. <h3>Report of a Case</h3> A 25-year-old man was admitted to a US Navy Hospital in the Philippine Islands on Aug 15, 1976, with a two-day history of fever, migratory arthritis, and transient red papules on his limbs. He had an effusion of the left knee, with a WBC count of 14,300/cu mm, with 85% polymorphonuclear leukocytes. Gram's stain and cultures of the synovial fluid were negative, and roentgenograms of his joints were normal. He was treated with oral penicillin G potassium, salicylates, and prednisone for possible acute rheumatic fever. Temperatures of 38
Put human cloning on hold, say bioethicists
Authors: C. Marwick
Journal: JAMA (1997)

HUMAN CLONING should be put on hold—but only temporarily, the National Bioethics Commission concluded in a report issued last month. "Clearly, there is a need for further public deliberation on the serious moral concerns raised by the prospect of cloning human beings," the commission said. President Bill Clinton asked the 18-member group in February to review the legal and ethical issues surrounding cloning and report back within 90 days. The president's request was a response to the report that researchers in Scotland had succeeded in cloning a sheep (<i>Nature</i>. 1997;385:810-813). The news sparked worldwide interest and concern that the cloning of humans was just around the corner. In a letter transmitting the Bioethics Commission report to the White House, chair Harold T. Shapiro, PhD, president of Princeton University, Princeton, NJ, said there is a need for a "great deal more widespread education and deliberation" to resolve the legal and moral
Clinical Features and Treatment of Pre-Ulcerative Buruli Lesions: REPORT II OF THE UGANDA BURULI GROUP
Journal: BMJ (1970)

At Kinyara, and in other areas of Uganda, 250 patients with pre-ulcerative Buruli lesions (Myco. ulcerans infection, have been seen over the past three years. The clinical feature of the pre-ulcerative stage of the disease are painless nodules, usually occurring singly on the legs or forearms. As the nodule can grow rapidly to become an extensive fulminating lesion, early recognition of the nodule and an appreciation of its significance by both doctor and patient are essential. Excision of the nodule is simple and usually curative, thus preventing ulcers developing and requiring prolonged hospital treatment.
Abstract 955: Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy
Authors: Daniel R. Principe, Matthew Narbutis, Sandeep Kumar, Alex Park, Navin Viswakarma, Matthew J. Dorman, Suneel D. Kamath, Paul Grippo, Melissa L. Fishel, Rosa F. Hwang, Dinesh Thummuri, Patrick W. Underwood, Hidayatullah G. Munshi, Jose G. Trevino, Ajay Rana
Journal: Cancer Research (2020)

Abstract Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death with a median survival time of 6-12 months. As most patients present with disseminated disease, the majority are offered palliative chemotherapy. With no approved treatment modalities for patients who progress on chemotherapy, we explored the effects of long-term Gemcitabine on the tumor microenvironment in order to identify potential therapeutic options in chemo-refractory PDAC. Using a combination of mouse models, patient-derived xenografts, primary and established cell lines, we first evaluated chemotherapy-induced alterations in the tumor secretome and immune surface proteins by high throughput proteomic arrays. In addition to enhancing antigen presentation and immune checkpoint expression, Gemcitabine consistently increased the synthesis of CCL/CXCL chemokines and TGFβ-associated signals. These secreted factors altered the composition of the tumor stroma, conferring Gemcitabine-resistance to cancer-associated fibroblasts in vitroand further enhancingTGFβ1 biosynthesis. We therefore combined Gemcitabine with anti-PD-1 in transgenic models of murine PDAC, which failed to alter disease course unless mice also underwent genetic or pharmacologic ablation of TGFβ signaling. In the setting of TGFβ signal deficiency, Gemcitabine and anti-PD-1 led to a robust CD8+ T-cell response and decrease in tumor burden, markedly enhancing overall survival. These results suggest that Gemcitabine may prime PDAC tumors for immune checkpoint inhibition by enhancing antigen presentation, but requires the inhibition of an immunosuppressive cytokine barrier. Given the current lack of third line treatment options, this approach warrants consideration in the clinical management of Gemcitabine-refractory PDAC. Citation Format: Daniel R. Principe, Matthew Narbutis, Sandeep Kumar, Alex Park, Navin Viswakarma, Matthew J. Dorman, Suneel D. Kamath, Paul Grippo, Melissa L. Fishel, Rosa F. Hwang, Dinesh Thummuri, Patrick W. Underwood, Hidayatullah G. Munshi, Jose G. Trevino, Ajay Rana. Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 955.
Research ethics, due process, and common sense
Authors: P. J. Friedman
Journal: JAMA (1988)

IN THIS issue ofTHE JOURNAL, Mishkin<sup>1</sup>has spelled out a tough-minded approach to research misconduct, arguing that science must enforce its standards more vigorously. This proposal demands prior notification, or the dissemination of "dos and don'ts" for researchers, more serious attention to whistle-blowers, and stricter rules for conducting investigations, so that due process may be strengthened along with the increased severity of potential sanctions. Mishkin illuminates the essential features of a university administration's guidelines for responding to charges of unethical conduct. These features include protection for the accused and the accuser, a graded response based on preliminary assessment of the seriousness of the charges and the likelihood of their validity, and a process of review that involves peers that are well informed but not involved with the questioned research. Logical as this approach is, the skeptical administrator sees some practical problems with it. For one thing, most scientists
MEDICAL ADVICE IN LAY PAPERS.
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New typhoid fever vaccine a hit on international scene
Authors: C. Macek
Journal: JAMA (1982)

The results of a recently completed field trial with a new live oral typhoid fever vaccine show promise that the disease, which is endemic in many parts of the world, eventually may be controlled. M. H. Wahdan, MD, and colleagues at the High Institute of Public Health, Alexandria, Egypt, the Pasteur Institute, France, and the Swiss Serum and Vaccine Institute, Bern, conducted a controlled trial in Alexandria with 32,388 first-grade schoolchildren. The results of the three-year study were published in the March issue of<i>The Journal of Infectious Diseases</i>. An attenuated mutant strain of<i>Salmonella typhi</i>was used as the immunogen in the study. Exposure to a high concentration of exogenous galactose (as occurs in the body) causes this strain to lyse within a day or two, but not before its cell wall lipopolysaccharides have provided the necessary antigenic stimuli. Although a number of<i>S typhi</i>strains exhibit this particular
Association News.
Journal: JAMA (1899)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Increased in-vivo expression of inducible cyclooxygenase-2 (Cox-2) in experimental alcoholic liver disease . Dept. Pathol., N.E. Deaconess Hosp. and Harvard Med. Sch. Boston, MA and *Cornell Med. Coll. and Anne Fisher Nutrition Ctr. at Strang Cancer Prev. Ctr; New York, NY
Journal: Hepatology (1995)
Age-Specific Carcinogenesis: Environmental Exposure and Susceptibility
Authors: Richard D. Thomas
Journal: Environmental Health Perspectives (1995)

Environmental exposures in children may occur through many routes, including diet, air, and the ingestion of various nonfood items such as medica- tions and household materials.This article focuses on dietary exposure, but it does highlight the importance of considering other routes of exposure when assessing exposure in children.It presents many of the findings in the two recent reports, Pesticides in the Diets of Infants and Children and Science and Judgment in Risk Assessment of the National Academy of Sciences (NAS)/National Research Council (NRC).Diet is an important source of exposure for children to potential carcinogens.The trace quantities of chemicals present on or in foodstuffs are termed residues.In addi- tion, there are substances that children may be exposed to in air and water that should be considered in a total exposure analysis.To minimize expo- sure of the general population to chemical residues in food, water, and air, the U.S. government has instituted regulatory controls.These are intended to limit exposures to residues while ensuring an abundant and nutritious food supply, and safe drinking water and air.The legislative frame- work for these controls was established by the Congress through various local and state laws and such federal laws as the Insecticide, Fungicide, and Rodenticide Act (FIFRA), the Federal Food, Drug, and Cosmetic Act (FFDCA), the Safe Drinking Water Act (SDWA), and the Clean Air Act JCAA).This article summarizes current approaches to assessing exposure and susceptibility in children.
How would you decide?
Journal: JAMA (1974)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Selenium Concentration in the Milk of Breast-Feeding Mothers and Its Geographic Distribution
Authors: Bronislaw Andrzej Zachara, Adam Pilecki
Journal: Environmental Health Perspectives (2000)

A total of 905 human milk samples collected in all provinces of Poland, between 12 and 75 days of lactation, were analyzed for selenium concentration. The distribution of Se levels in milk between the provinces was narrow and varied from 8.81 to 11.58 ng/mL, with the mean value (+/- SD) of 10.24 +/- 2.82 ng/mL. The regions with lower levels of Se were in the central and eastern part of Poland; the areas with higher values were in the northern, western, and southern parts of Poland. No significant correlations were found between Se levels in milk and the age of lactating mothers or between Se levels and the postpartum period. The calculated daily Se intakes by breast-fed infants varied from 6.46 to 8.50 microg/day, with the mean value of 7.52 microg/day. This amount does not meet the recommended dietary allowances for infants between 0 and 6 months of age. Based on Se levels in human milk, we present a selenium map of Poland.
ENDOCRINE SURGERY AND THE TREATMENT OF CARCINOMA OF THE BREAST
Journal: JAMA (1961)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
New and Nonofficial Remedies, 1927, containing descriptions of the articles which stand accepted by the Council on Pharmacy and Chemistry of the American Medical Association on Jan. 1, 1927.
Journal: JAMA (1927)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0116 Efficacy of Glucocorticoids for Early Rheumatoid Arthritis (RA): A Meta-Analysis of Randomised Controlled Trials:
Authors: C. Gaujoux-Viala, S. Mitrovic, T. Barnetche, T. Schaeverbeke, L. Gossec
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Glucocorticoids are among the most used and most discussed treatment option for early RA. <h3>Objectives</h3> The aim of this study is to evaluate the structural and clinical efficacy of corticotherapy (CT) for recent-onset RA. <h3>Methods</h3> We carried out a systematic literature review on PubMed, EMBASE and Cochrane library until July 2013. The research was manually completed by the analysis of all references identified and of all abstracts presented at ACR and EULAR conferences of the past two years. All randomised placebo-controlled trials conducted on adult patients recently diagnosed (&lt;3 years) with RA were selected. Effect Size (ES) and pooled Odds-Ratios were calculated by meta-analysis. In case of significant heterogeneity, random-effects model was used. Sensitivity analyses were based on the dose used (low-dose ≤10mg/day of equivalent prednisone and high-dose) and duration of treatment. <h3>Results</h3> Out of 1367 articles, 18 were analysed. These were based on 14 randomised controlled trials involving a total of 2647 patients (mean age=54 years, 67% of women, mean of RA progression=5.4 months). Ten studies were based on low-dose CT and 4 on high-dose CT. We observed a significant higher frequency of remission DAS28 at 3, 6, 12 and 24 months in the CT group. Less structural progressions at 2 years in CT treated patients were also observed (table). <h3>Conclusions</h3> CT associated with background treatment of recent-onset RA is quickly effective and induces more remissions at short and medium-term (&lt;2 years) as well as structural benefit. Although safety data must be taken into account, low-dose CT may be recommended in the initial phase on early RA. <h3>Disclosure of Interest</h3> : None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5840
Surgeon General Illinois State Natonal Guard
Journal: JAMA (1893)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Correction
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal